ScreenerHero

MDXG MiMedx Group, Inc.

NAS · US · Healthcare · Biotechnology · mimedx.com
4.610USD-0.22%Mkt Cap: 672.76M $P/E: 115.25

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
MiMedx (MDXG) Q2 2026 Earnings Call Transcript

Surgical revenue grew 15% as wound care stabilized ahead of $350M Sanara deal.

Motley Fool
MiMedx Group, Inc. Q2 2026 Earnings Call Summary

Moby summary of MiMedx Group, Inc.'s Q2 2026 earnings call

Moby
MiMedx Group Inc (MDXG) (Q2 2026) Earnings Call Highlights: Surgical Growth and Transformative ...

MiMedx reports strong surgical momentum and a transformational acquisition, while navigating a challenging wound care market with early signs of stabilization.

GuruFocus.com
MiMedx Group Q2 Earnings Call Highlights

MiMedx Group (NASDAQ:MDXG) said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx’s second-quarter results, which showed sequential improvement in its wound-care busines

MarketBeat